Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Notice to Readers Availability of Parenteral Quinidine Gluconate for Treatment of Severe or Complicated Malaria

CDC has received reports of two fatal cases of Plasmodium falciparum malaria in the United States in which a delay in obtaining quinidine gluconate for intravenous therapy was thought to have played a role in the patients' deaths. Since 1991, quinidine gluconate, a well-known and widely used class Ia anti-arrhythmic agent, has been the only parenteral antimalarial drug available in the United States. It is the drug of choice for treating serious and life-threatening malaria infections and is active against drug-resistant strains of P. falciparum. Intravenous quinidine is indicated whenever oral therapy is not possible, in high-density infections (greater than 5% of red blood cells infected), and in the presence of complications such as cerebral malaria or acute renal failure.

As newer anti-arrhythmic agents have replaced quinidine for many of its cardiac indications, some hospitals and health facilities have dropped quinidine gluconate from their formularies. Although most patients with malaria reported in the United States are treated with oral medication and recover fully, a small number of fatal cases occur each year, often associated with substantial delays in seeking treatment or in initiating appropriate antimalarial therapy. Because of this potential problem, directors of hospital drug services should take into account the essential role of quinidine gluconate in treating patients with severe and complicated malaria before removing it from their formularies. Hospitals within close geographic proximity are encouraged to coordinate their respective formularies so that quinidine gluconate

Reported by: Food and Drug Administration. Div of Parasitic Diseases, National Center for Infectious Diseases, CDC.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version ( and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #